Previous close | 0.2500 |
Open | 0.2300 |
Bid | 0.1500 |
Ask | 0.2500 |
Strike | 7.50 |
Expiry date | 2024-07-19 |
Day's range | 0.1500 - 0.2300 |
Contract range | N/A |
Volume | |
Open interest | 230 |
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.